8-K: InspireMD Secures Landmark FDA Approval for CGuard Prime Carotid Stent System for Stroke Prevention

InspireMD, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) for its CGuard Prime Carotid Stent System, a significant milestone for stroke prevention.

Summary

• InspireMD, Inc. received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its CGuard Prime Carotid Stent System on June 23, 2025, for the prevention of stroke.
• The FDA approval is supported by best-in-class evidence from the C-GUARDIANS pivotal trial, which enrolled 316 patients across 24 sites in the United States and Europe.
• The C-GUARDIANS trial demonstrated CGuard Prime's superior safety and efficacy, reporting the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention.
• This approval triggers the second of four milestone-driven warrant tranches from a May 2023 private placement, with expected gross proceeds of $17.9 million if fully exercised.
• The proceeds from the warrant exercise are intended to fund the imminent U.S. commercial launch of CGuard Prime, initiate new regulatory pathways for advanced applications, and develop new products.
• CGuard Prime utilizes proprietary MicroNet mesh technology, designed to provide durable embolic protection by preventing plaque protrusion through the stent.
• Globally, over 65,000 CGuard implants have been sold to date, with studies involving over 2,000 patients.

Sentiment

Score: 9

Explanation: The FDA PMA approval is a transformative event for the company, opening up the significant U.S. market for a product with demonstrated best-in-class clinical outcomes. This is a major de-risking event and provides a clear path to commercialization and potential revenue growth, despite existing financial challenges.

Positives

• Received FDA Premarket Approval (PMA) for the CGuard Prime Carotid Stent System, opening the significant U.S. market.
• CGuard Prime demonstrated best-in-class clinical outcomes with the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention.
• The C-GUARDIANS trial results are consistent with a large body of evidence from outside the United States, reinforcing the device's efficacy and safety.
• The FDA approval triggers a milestone-driven warrant tranche, potentially providing $17.9 million in gross proceeds to support commercial launch and future development.
• CGuard Prime's unique MicroNet mesh technology offers durable embolic protection, a next-generation advancement in the carotid field.
• The product has an established global track record with over 65,000 implants sold and studies in over 2,000 patients.

Negatives

• The company has a history of recurring losses and negative cash flows from operating activities.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company faces significant future commitments and uncertainty regarding the adequacy of its liquidity to pursue its complete business objectives.
• Future capital raises may be costly or difficult to obtain and could dilute existing stockholders' ownership interests.

Risks

• History of recurring losses and negative cash flows from operating activities.
• Substantial doubt about the company's ability to continue as a going concern.
• Significant future commitments and uncertainty regarding the adequacy of liquidity to pursue complete business objectives.
• Need to raise additional capital in the future, which may be costly or difficult to obtain and could dilute stockholders' ownership interests.
• Market acceptance of products.
• Inability to secure and maintain regulatory approvals for product sales.
• Negative clinical trial results or lengthy product delays in key markets.
• Ability to maintain compliance with Nasdaq listing standards.
• Ability to generate revenues from products and obtain and maintain regulatory approvals.
• Ability to adequately protect intellectual property.
• Dependence on a single manufacturing facility and ability to comply with stringent manufacturing quality standards and to increase production as necessary.
• Risk that the data collected from current and planned clinical trials may not be sufficient to demonstrate that the technology is an attractive alternative to other procedures and products.
• Intense competition in the industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources.
• Entry of new competitors and products and potential technological obsolescence of products.
• Inability to carry out research, development and commercialization plans.
• Loss of a key customer or supplier.
• Technical problems with research and products and potential product liability claims.
• Product malfunctions.
• Price increases for supplies and components.
• Insufficient or inadequate reimbursement by governmental and other third-party payers for products.
• Efforts to successfully obtain and maintain intellectual property protection covering products may not be successful.
• Adverse federal, state and local government regulation, in the United States, Europe or Israel and other foreign jurisdictions.
• Conducting business in multiple foreign jurisdictions, exposing the company to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction.
• Escalation of hostilities in Israel, which could impair manufacturing ability.
• Current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk.

Future Outlook

The company plans an immediate and aggressive U.S. commercial launch of the CGuard Prime Carotid Stent System. Proceeds from the warrant exercise will also be used to initiate new regulatory pathways for advanced applications of the CGuard stent platform and develop new products, while continuing to develop its business outside the United States.

Management Comments

• "I am proud to announce the PMA approval of CGuard Prime, our best-in-class carotid stent system. This is a pivotal milestone for the Company after many years of commitment to bringing this innovative stent platform to patients in the United States." Marvin Slosman, Chief Executive Officer of InspireMD.
• "The significance of CGuard Prime to the shift toward less invasive carotid artery revascularization is tremendous. Our approval marks a true breakthrough in the treatment of carotid disease." Marvin Slosman, Chief Executive Officer of InspireMD.
• "Our innovation is built around the protective MicroNet mesh barrier providing durable protection and preventing post procedural events, a unique and next generation advancement in the carotid field." Marvin Slosman, Chief Executive Officer of InspireMD.
• "With over 65,000 implants sold to date and studies in over 2,000 patients, CGuard Prime offers an established and tested advancement to patient care." Marvin Slosman, Chief Executive Officer of InspireMD.
• "CGuard Prime now offers an important frontline, proven technology for treatment of United States patients with obstructive carotid artery disease, and continued benefits to patients worldwide." Dr. D. Chris Metzger, System Vascular Chief at OhioHealth and U.S. Primary Investigator for the C-GUARDIANS trial.
• "These excellent results were in patients who were at high risk for carotid endarterectomy, a quarter of whom were symptomatic." Dr. D. Chris Metzger.

Industry Context

The FDA approval of CGuard Prime represents a significant advancement in the carotid stenting market, supporting the broader industry trend towards less invasive revascularization procedures for stroke prevention. Its demonstrated low adverse event rates position it as a potentially leading technology in the competitive carotid intervention space, offering a new frontline treatment option for patients with obstructive carotid artery disease in the U.S.

Comparison to Industry Standards

• CGuard Prime demonstrated the lowest 30-day (0.95%) and 1-year (1.93%) primary endpoint major adverse event rates of any pivotal study of carotid intervention.
• The C-GUARDIANS clinical trial results, consistent with a large body of evidence from outside of the United States, demonstrate the lowest event rates (stroke, death and MI to 30 days and ipsilateral stroke at 1 year) ever reported in any trial of carotid revascularization.

Stakeholder Impact

• Shareholders: Positive impact due to FDA approval, potential for increased revenue, and capital infusion from warrant exercise.
• Patients: Access to a new, highly effective, and less invasive treatment option for carotid artery disease with demonstrated superior safety outcomes.
• Healthcare Providers: New frontline, proven technology for treating obstructive carotid artery disease.
• Employees: Potential for growth and expansion with U.S. market entry.

Next Steps

• Immediate and aggressive U.S. commercial launch of the CGuard Prime Carotid Stent System.
• Initiating new regulatory pathways for advanced applications of the CGuard stent platform.
• Developing new products.
• Continuing to develop business outside of the United States.

Key Dates

Recommendation

Keywords

InspireMD, CGuard Prime, Carotid Stent System, FDA Approval, PMA, Stroke Prevention, Medical Device, Cardiovascular, MicroNet mesh, C-GUARDIANS trial, NSPR, Carotid Artery Stenosis, Interventional Cardiology, Neuro-protective